1. Introduction {#sec1}
===============

Breast cancer (BC) is the first female cancer and the leading cause of cancer death in women in France \[[@bib1]\] and worldwide \[[@bib2]\]. Latest French data show an estimated annual mortality rate of 11 833 women (2017) [@bib3], and interestingly, overall survival (OS) at 5 years differs among age groups: 90% before 45 years old (y), 92% between 45 and 55y, 89% between 55 and 65y, 87% between 65 and 75y, and 58% after75y [@bib1]. In early stage BC, young age is a known poor prognostic factor \[[@bib4], [@bib5], [@bib6]\]. Aggressive subtypes, like triple negative, are more frequent in young patients. However, young age has been found to be an independent prognostic factor in most studies \[[@bib4],[@bib7]\], sometimes only in luminal subtypes \[[@bib8],[@bib9]\].

In metastatic breast cancer (MBC), recognized poor prognostic factors are short metastasis-free interval, visceral involvement and crisis, negative hormone receptor (HoR) and particularly triple negative subtype, primary endocrine resistance for luminal subtype and number of metastatic sites \[[@bib10]\]. However, the prognostic impact of age remains unclear in this clinical setting. Several retrospective series have unexpectedly suggested that older women had a poorer prognosis than women under 50 years of age \[[@bib11], [@bib12], [@bib13]\]. Nonetheless, international guidelines state that age should not guide the treatment strategy and the intensity of treatment, especially to avoid overtreatment in young patients \[[@bib10],[@bib14]\].

Real-world data are important assets as they provide data from large data sets with long follow-up which usefully complements data from randomized clinical trials. The Epidemiological Strategy and Medical Economics (ESME) program is an academic initiative launched in 2014 by UNICANCER, the French network of cancer centers, to report exhaustive, high quality and centralized real-life data on different solid tumors including MBC. It allowed building a database of more than 16 000 MBC cases. The ESME Research program included 3 types of cancer: MBC, ovarian and lung cancers. It involves 18 academic cancer centers managing together over one-third of all BC cases nationwide; for MBC, other citations are available \[[@bib15], [@bib16], [@bib17], [@bib18]\]. We used the ESME MBC database (NCT03275311) to evaluate the impact of age at MBC diagnosis on overall survival (OS).

2. Patients and methods {#sec2}
=======================

2.1. Study design {#sec2.1}
-----------------

The ESME MBC database is a unique national cohort, collecting retrospective data using clinical trial-like methodology. It included all consecutive MBC patients (pts) who initiated at least one treatment in one of the 18 participating French cancer centers between January 01, 2008 and Decemeber 31, 2014. Follow-up data have been collected until October 11, 2016, death or date of latest news. Exclusion criteria were: patients treated for another cancer in the last 5 years before MBC diagnosis, with unknown ER/PR/Her2 status, or men (who will be analyzed in a separate study \[[@bib19]\]).

We carried out a retrospective, comparative study to assess overall survival of MBC patients selected from the ESME MBC database among 3 age groups (\<40, 40 to 60 and \> 60 y).

The ESME research program is handled by R&D Unicancer in accordance with current best practice guidelines and rules (Good pharmacoepidemiology pratices). The program is monitored by an independent scientific committee who approved the present work. The ESME MBC database \[[@bib20]\] was authorised by the French data protection authority (\[Registration ID 1704113 and authorisation N°DE-2013.-117\], NCT03275311). All data are exclusively obtained retrospectively. The present analysis was approved by an independent ethics committee (Comité de Protection des Personnes Sud-Est II-2015-79). Considering the retrospective design of the study, no informed consent was deemed necessary. Nevertheless, all patients were informed about the re-use of their electronically recorded data.

Subtypes were defined according to the first histology available (primary tumor), otherwise on the metastasis. HoR + status was defined as ER+/PR+; ER+/PR- or missing; ER- or missing/PR+. HoR positivity was defined if nuclear staining was strictly superior to 10% in immunochemistry. HER2+ status was established if HER2 was found 3+ in IHC or 2+ with amplified FISH or CISH. De novo MBC was defined by the diagnosis of a metastasis within 90 days of the primary tumor. Among de novo MBC, loco-regional treatment was defined as breast surgery (mastectomy or lumpectomy) and/or loco-regional radiotherapy (including breast±regional lymph nodes) within the first year of diagnosis. OS was defined as the time between the diagnosis of metastasis and the date of death (from any cause), or censored to the date of latest news.

2.2. Objectives {#sec2.2}
---------------

The primary endpoint of this study was the evaluation of the impact of age at MBC diagnosis on OS, among 3 age groups (\<40, 40 to 60 and \> 60 y). Main secondary endpoints were the description of MBC features in each age group and evaluation of OS by breast cancer subtype in each age group.

2.3. Statistical analysis {#sec2.3}
-------------------------

Clinical, pathological and treatment characteristics were described overall and across age groups by their distribution for categorical data, and their mean and median for continuous data. Comparisons between age groups were performed using Chi-squared tests or Fisher's exact test for categorical data and non-parametric Wilcoxon's test for continuous data. A *p*-value \<0.05 was considered statistically significant.

Median follow-up was calculated using reverse Kaplan-Meier estimation.

For OS, survival curves were determined using the Kaplan-Meier method; survival medians were given with their 95% confidence interval (CI). Survival curves were compared using log-rank tests. Hazard-ratio with their 95% CI were computed using a univariate Cox model; all significant factors were included in a multivariate Cox model. Survival analysis were conducted in the whole population and in each subtype group.

3. Results {#sec3}
==========

Among 16 703 included pts, 1810 had no information available in the database on tumor receptors (ER/PR/HER2) and 490 had at least one exclusion criterion (unknown age, men, other cancer in the last 5y), leaving 14 403 for analysis ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Study flow diagram.Fig. 1

3.1. Patients \<40y had more frequent aggressive features at both primary disease and first metastatic event {#sec3.1}
------------------------------------------------------------------------------------------------------------

Data relative to TNM stage of the primary tumor were partly retrieved ([Table 1](#tbl1){ref-type="table"}). Tumors occurring in women aged \<40y showed more aggressive features. Grade III tumors were recorded in 62.3%, 48.2% and 39.9% in patients \<40, 40--60 and \> 60 y respectively (p \< 0.0001). HoR-/HER2-tumors were observed in 26.8%, 19.4% and 14.0% of patients \<40, 40--60 and \> 60 y respectively, and Her2+ subtype in 25.7%, 20.6% and 15.7% of patients \<40, 40--60 and \> 60 y respectively (p \< 0.0001). Details of adjuvant treatments are described in [Table 1](#tbl1){ref-type="table"}.Table 1Characteristics of primary tumor and adjuvant treatment: overall and across age groups(∗%/available data; ∗∗%/all patients).Table 1All\
N = 14403Age at MBCP value between age groups\<40\
N = 107740--60 years\
N = 6436\>60 years\
N = 6890NN%N%N%**Tumor size (cT)\<0.0001**T016440.7%∗752.5%∗852.8%∗T112977513.4%∗54817.9%∗67422.4%∗T2238921037.6%∗111936.6%∗106035.3%∗T3119215628.0%∗61720.2%∗41913.9%∗T4 global157911320.3%∗69822.8%∗76825.5%∗*Not avalaible778251948.2%∗∗337952.5%∗∗388456.4%∗∗***Nodal status (cN)\<0.0001**N0274018334.7%∗120141.5%∗135648.6%∗N1251324245.9%∗123542.6%∗103637.1%∗N25756312.0%∗2739.4%∗2398.6%∗N3386397.4%∗1886.5%∗1595.7%∗Not available818955051.1%∗∗353955.0%∗∗410059.5%∗∗**Grade\<0.0001**I915262.6%∗3465.9%∗5438.8%∗II624735235.1%∗271145.9%∗318451.3%∗III594762462.3%∗284748.2%∗247639.9%∗Not available1294757.0%∗∗5328.3%∗∗68710.0%∗∗**Histological type\<0.0001**Ductal1131797397.0%∗528189.3%∗506380.8%∗Lobular1868303.0%∗63610.7%∗120219.2%∗Other or Not available1218746.9%∗∗5198.0%∗∗6259.0%∗∗**Subtypes\<0.0001**HoR + Her2-839150247.5%∗360460.0%∗428570.3%∗HoR-Her2-229828326.8%∗116319.4%∗85214.0%∗Her2+246527125.7%∗123820.6%∗95615.7%∗Not available1249211.9%∗∗4316.7%∗∗79711.6%∗∗**Adjuvant chemotherapy\<.0001**Yes750269964.9%∗391360.9%∗289042.1%∗No687037835.1%∗251539.1%∗397757.9%∗Not available3100.0%∗∗80.1%∗∗230.3%∗∗**Adjuvant radiotherapy0.1309**Yes888063458.9%∗399762.2%∗424961.8%∗No549344140.9%∗242937.8%∗262338.2%∗Not avalaible3020.2%∗∗100.2%∗∗180.3%∗∗**Adjuvant endocrine therapy\<.0001**Yes669538035.3%∗283844.1%∗347750.5%∗No767769564.5%∗358355.7%∗339949.3%∗Not avalaible3120.2%∗∗150.2%∗∗140.2%∗∗

At the onset of MBC, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were \<40, 40--60 and \> 60 y respectively. De novo metastatic disease occurred in 4124 patients (28.6%), more frequently in younger patients: 31.5%, 28.7 and 27.1% in patients \<40, 40--60 and \> 60 y respectively (p = 0.003). Younger patients had also a shorter time to first metastasis: 28.6% between 3 and 24 months versus 12.5% in patients \>60y. Overall, median time to metastasis was shorter in younger patients: 18 months in \<40y, 27 months in 40--60y and 42 months in \>60y (p \< 0.0001) which might be in line with subtype distribution.

Similarly, at metastatic disease onset, patients \<40y also had significantly more aggressive presentations than other age groups (data are shown across age groups: \<40, 40--60 and \> 60 y respectively): more frequent visceral involvement (36.3%, 33.3% and 29.8%), more frequent HER2+ (26.6%, 21.2% and 16.1%), and HoR-/Her2- (25.3%, 17.7% and 12.1%) subtypes, (all p-value vs other age groups \<0.0001) \[Details are specified in [Table 2](#tbl2){ref-type="table"}\].Table 2Metastatic breast cancer characteristics according to age groups.Table 2AllAge at MBC*P value between age groups*\<40 years\[40--60\] years\>60 yearsN%N%N%N%***Time to first metastasis***\<0.0001*De novo (\<* 3 months*)*405828.2%33931.5%184928.7%187027.1%*\[3--24\[ months*228415.9%30828.6%111417.3%86212.5%*\>=* 24 months803555.8%42939.8%346153.8%414560.2%*NA*260.2%10.1%120.2%130.2%***Number of metastatic sites***0.02*One site*797655.4%57253.1%349354.3%391156.8%*Two sites*347324.1%26724.8%158624.6%162023.5%*Three or more sites*295420.5%23822.1%135721.1%135919.7%***Type of metastasis***\<0.0001*Bone only*814565.3%56252.2%358755.7%399658.0%*Visceral*458415.6%39136.3%214033.3%205329.8%*Other (neither visceral nor bone)*167419.1%12411.5%70911.0%84112.2%***Tumor subtype***\<0.0001*HoR + HER2-*939815.6%51948.2%393461.1%494571.8%*HoR-HER2-*224719.1%27225.3%113817.7%83712.1%*HER2+*275865.3%28626.6%136421.2%110816.1%**De novo MBC --treatment of primary tumor \<1y from diagnosis**Breast surgery69117.0%9026.5%37420.5%22712.1%0.001Loco-regional RT133332.8%17351.0%70538.1%45524.3%\<0.0001

3.2. First line treatments for metastatic breast cancer {#sec3.2}
-------------------------------------------------------

First-line treatments for MBC differed across age groups among all subtypes. In HoR+/HER2-younger patients received more frequently chemotherapy (80.5%, 60.8% and 47.4% in the 3 age groups respectively; p \< 0.0001) and less endocrine therapy (70.1%, 75.6% and 81.3%; p \< 0.0001). In Her2+ subtype, chemotherapy as well as anti-Her2 treatments were more frequently administered to younger patients: 80.5%, 68.5% and 47.4% across age groups for chemotherapy (p \< 0.0001); 87.1%, 81.7% and 75% for anti-Her2 treatments (p \< 0.0001). A similar trend was observed in HoR-/HER2-patients. Details are shown in [Table 3](#tbl3){ref-type="table"}.Table 3First-line treatments according to tumor subtypes and age groups.Table 3AllAge groups (years)P value between age groups\<4040--60\>60N%N%N%N%**HoR+/HER2**Chemotherapy545658.1%41880.5%269368.5%234547.4%\<0.0001Endocrine therapy735878.3%36470.1%297475.6%402081.3%\<0.0001**Her2+**Chemotherapy246989.5%27395.5%125792.2%93984.7%\<0.0001Endocrine therapy113141.0%13446.9%49436.2%50345.4%\<0.0001Anti-Her2219579.6%24987.1%111581.7%83175.0%\<0.0001**HoR-/HER2-**\<0.0001Chemotherapy210993.9%26296.3%109296.0%75590.2%\<0.0001

3.3. Loco-regional treatment of the primary tumor in de novo MBC {#sec3.3}
----------------------------------------------------------------

Among patients with de novo MBC, loco-regional treatment was more frequent in patients \<40y: breast surgery (breast-conserving or mastectomy) was performed in 26.5% of patients \<40y, 20.5% in the 40-60y group and 12.1% in \>60y group; loco-regional radiotherapy was performed in 51% of patients \<40y, 38.1% in the 40-60y group and 24.3% in the \>60y group.

3.4. Overall survival differs after first metastatic event according to age and subtype {#sec3.4}
---------------------------------------------------------------------------------------

Median follow-up was 48 months. Median OS significantly differed across age groups, and was 38.8, 38.4 and 35.6 months for pts \<40, 40--60 and \> 60y, respectively (p \< 0.0001). Compared to pts \>60y, younger pts had a slightly significant lower risk of death (all causes of death included): HR = 0.91, CI 95% 0.83--0.99. This trend for a longer OS was confirmed in patients \<40 in HoR+/HER2-and Her2+ subtypes, but not in HoR-/Her2- MBC \[[Fig. 2](#fig2){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}\].Fig. 2Overall survival according to age and tumor subtypes.Fig. 2Table 4Uni- and multi-variate analysis of factors impacting on overall survival.Table 4Cox univariateCox multivariateHR (95% CI)pHR (95% CI)pAge at MBC\>60 years1\<0.00011\<0.0001\[40--60\]0.90 (0.86--0.94)0.84 (0.80--0.88)\<40 years0.91 (0.83--0.99)0.75 (0.69--0.82)Time to MBC≥24 months1\<0.00011\<0.0001\[3--24\[ months2.00 (1.89--2.12)1.88 (1.77--1.99)De novo (\<3 months)0.83 (0.79--0.88)0.84 (0.80--0.89)SubtypeHoR + HER2-1\<0.00011\<0.0001HoR-HER2-2.72 (2.58--2.88)2.48 (2.34--2.63)HER2+0.89 (0.83--0.94)0.87 (0.81--0.92)Number of metastatic sitesOne site1\<0.00011\<0.0001Two sites1.40 (1.33--1.48)1.40 (1.32--1.48)Three or more sites1.93 (1.82--2.03)1.99 (1.88--2.11)Metastatic siteBone1\<0.00011\<0.0001Visceral1.19 (1.13--1.25)1.10 (1.05--1.16)Other (neither visceral nor bone)0.80 (0.74--0.86)0.77 (0.71--0.84)

Univariate analysis suggested that young age was a favorable prognostic factor in MBC. Multi-variate analysis confirmed that young age was an independent prognostic factor when controlling for other factors in patients with MBC. Indeed, compared to patients \>60y, hazard ratio for death was 0.75 (95% CI 0.69--0.82) in patients \<40y and 0.84 (95% CI 0.80--0.88) in patients aged 40-60y (p \< 0.0001). Other expected prognostic factors were confirmed: longer time to MBC and de novo disease \[HR for death 1.88 (95% CI 1.77--1.99) for patients relapsing between 3 and 24 months, 0.84 (95% CI 0.80--0.89) for de novo MBC, all compared to patients relapsing after 24 months (p \< 0.0001)\], subtype \[HR 2.48 (95% CI 2.34--2.63) for the HoR-/HER2-subset, 0.87 (95% CI 0.81--0.92) for Her2+ compared to HoR + HER2- (p \< 0.0001)\], number of metastatic sites \[HR 1.40 (95% CI 1.32--1.48) for 2 sites, 1.99 (95% CI 1.88--2.11) for 3 or more sites compared to one (p \< 0.0001)\], and type of metastatic sites \[HR 1.10 (95% CI 1.05--1.16) for visceral involvement, 0.77 (95% CI 0.71--0.84) for neither visceral nor bone compared to bone only (p \< 0.0001)\]. Details are shown in [Table 4](#tbl4){ref-type="table"}.

4. Discussion {#sec4}
=============

Our study analyzed real-world data on MBC across three commonly accepted age groups \<40; 40--60 and \> 60 years old. Our primary objectives were to describe metastatic breast cancer clinical characteristics according to age in order to evaluate its impact on overall survival, and to analyze the relationship between age and BC subtype at the metastatic stage.

This unique real-world database of a large cohort of patients with MBC demonstrated that young patients had not only, more aggressive presentations in primary tumors but also at the time of metastatic disease, most likely associated with subtype distribution. Indeed, patients under 40y exhibited more frequently three or more metastatic sites and visceral involvement, and had also more frequent HER2+ or triple negative subtypes ([Table 2](#tbl2){ref-type="table"}). These features had been identified as independent poor prognostic factors in a previous global report of the ESME MBC cohort \[[@bib21]\]. Despite this poor risk presentation, and contrary to what is commonly observed in early breast cancer, OS was significantly longer in young patients in the present cohort: 38.8, 38.4 and 35.6 months for pts \<40, 40--60 and \> 60y, respectively (p \< 0.0001). Specifically, OS was significantly better for young patients with HoR+/Her2-or Her2+ subtypes: HR comparing \<40y to \>60y was 1.27 (95%CI 1.12--1.44) and 1.62 (95%CI 1.32--1.99) respectively ([Fig. 2](#fig2){ref-type="fig"}). No difference was found in the triple negative subtype, where patients suffered a poor survival rate in all age groups. The multivariate analysis demonstrated that age \<40y, HER2+ subtype and de novo metastatic disease were all independent favorable prognostic factors, along with disease limited to one site or neither visceral/nor bone sites ([Table 4](#tbl4){ref-type="table"}).

The independent favorable impact of young age on overall survival in metastatic breast cancer has been previously reported. One of the main ESME MBC report, which focused on overall survival time trends, showed that each incremental year of age was independently and significantly associated with a higher hazard ratio for death: HR 1.02 per additional year in the HoR+/HER2-and HER2+ subsets (p \< 0.001) [@bib21]. Similarly, in a large cohort of metastatic breast cancer from the SEER database, age under 50 was also found to be a favorable prognostic factor among 4932 patients including 850 patients (5%) under 50 years old \[[@bib22]\]. Of note, aggressive phenotypes were also more frequent in younger patients in this cohort, again showing no negative impact on OS. On the contrary, overall and breast-cancer specific survivals were significantly better in younger patients compared to middle-aged patients (50--69 y): HR 0.77 (95%IC 0.68--0.87; p \< 0.001) and HR 0.81 (95%IC 0.71--0.92; p = 0.002) respectively. In other cohorts as well, younger age was significantly associated with better prognosis, in uni- and multi-variate analysis \[[@bib11], [@bib12], [@bib13]\].

A possible explanation for the difference in prognosis across age groups could be the less frequent use of chemotherapy. in older patients. Especially in Her2+ MBC chemotherapy as well as anti-Her2 treatments was less frequently used in older patients, possibly due to comorbidities, and could explain the negative impact on OS in patients \>60y.

However, in HoR+/Her2-subtype, a dedicated analysis of the same ESME cohort showed that endocrine therapy as first line treatment was not associated with a significant impact on OS and PFS in the entire cohort \[[@bib23]\] as well as in patients ≤45 years old \[[@bib24]\]. Furthermore, young age is less frequently associated with co-morbidities and frailty. Conversely, older age may limit the possibility to prescribe and sustain treatments, and be associated with more frequent competitive causes of death [@bib9], [@bib25], [@bib26]*.*

For patients with de novo metastatic disease, a potential explanation for the impact of age on OS, is a higher rate of loco-regional treatments in younger patients. Loco-regional treatments are known to be more frequently performed in younger patients and to be associated with better outcomes \[[@bib17],[@bib27], [@bib28], [@bib29]\]. Furthermore, recent prospective data also suggested that locoregional treatment of de novo MBC may improve long term prognosis \[[@bib30]\].

This study has several limitations. Causes of death were mostly unknown (52.1% of the total cohort, probably due to the retrospective collection of data), and this hampers our interpretation of overall survival. This is particularly true in the elderly population, where underlying comorbidities and other medications may limit the use of cancer treatments, and/or favor more severe and potentially lethal adverse events, again limiting therapeutic options. Competitive causes of death in elderly patients may also blur the meaning of overall survival, and breast cancer specific survival might be a more suitable endpoint. Another important limitation is the absence of information on the biology of metastatic disease. It has been widely demonstrated that the biological subtype may differ between the primary tumor and the metastatic tissue, notably for HoR + breast cancer \[[@bib31]\]. Of note, age did not impact overall survival in HoR-/HER2-patients, and triple negative disease is the less prone to subtype change. Finally, follow-up was collected until on October 2016, before wide use of novel therapeutic agents having shown positive impact on OS (e.g. CDK4/6 inhibitors). These targeted agents are widely prescribed also in elderly women, which may positively impact outcomes, warranting future real-life evaluations.

5. Conclusion {#sec5}
=============

Although young age seems to be associated with a more aggressive presentation at diagnosis of MBC, it does not affect OS in this large serie. On the contrary, young age was associated with a better prognosis, particularly among HoR+/Her2-and Her2+ subtypes, possibly linked to a more frequent use of chemotherapy and anti-Her2 treatments. Further studies should question the possible under-treatment of older patients, and try tailoring treatments to compensate for poor prognosis.
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